The purpose of this investigation was to define the cardiac effects of complement-derived C3a anaphylatoxin, in view of the possibility that cardiac dysfunction may occur as a result of complement activation. Purified human C3a was administered by intracoronary bolus injections into isolated guinea pig hearts. As a function of dose, C3a caused tachycardia, impairment of atrioventricular conduction, left ventricular contractile failure, coronary vasoconstriction, and histamine release. These effects were abolished by cleavage of the COOH-terminal arginine by carboxypeptidase B. The magnitude of C3a-induced tachycardia correlated with the amount of endogenous cardiac histamine released into the coronary effluent. Whereas the tachycardia was markedly reduced by the histamine H2 antagonist cimetidine, the contractile failure and the coronary vasoconstriction caused by C3a were antagonized by the leukotriene antagonist FPL 55712 and by the cyclooxygenase inhibitor indomethacin, respectively. This suggests that histamine, leukotrienes, and vasoactive prostanoates may mediate the various cardiac effects of C3a. Our findings indicate that C3a anaphylatoxin has marked cardiac effects at concentrations that are likely to be attained with a degree of C3 activation commonly seen in various disease states. Thus, our data are compatible with the hypothesis that generation of anaphylatoxins may induce cardiac dysfunction in clinical conditions. The complement system plays a primary role in normal host defense mechanisms, and its activation is commonly associated with human disease (1). A consequence of complement activation by the classical or alternative pathway is the production of C3a and C5a anaphylatoxins. These low molecular weight biologically active peptides are specifically cleaved from the parent molecules C3 and C5, respectively, during the activation process. These factors exhibit a variety of activities, such as smooth muscle contraction, chemotaxis, enhanced vascular permeability, and release of a number of mediators, such as histamine, leukotrienes, prostaglandins, thromboxane, and platelet-activating factor (2). High C3a and/or C5a plasma levels are known to occur during immediate hypersensitivity reactions (3-5, 36). Previous studies from our laboratory have demonstrated that mediators of immediate hypersensitivity cause severe cardiac dysfunction (6-9). Earlier reports from other investigators have attributed some degree of cardioactivity to crude anaphylatoxin preparations (10,11). Thus, it is conceivable that when complement is activated and anaphylatoxins are generated, cardiac dysfunction may ensue. The purpose of our investigation was to define the cardiac pharmacology of purified human C3a anaphylatoxin and to assess the role of various hypersensitivity mediators in the cardiac effects of C3a. We report that C3a has potent effects in the isolated guinea pig heart and that these consist of tachycardia, arrhythmias, left ventricular contractile failure, and coronary vasoconstriction.
MATERIALS AND...